Risque de zona au cours des traitements anti-TNF chez les patients atteints de polyarthrite rhumatoïde : revue systématique de la littérature et méta-analyse

Listing, 2005, Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis Rheum, 52, 3403, 10.1002/art.21386 Galloway, 2011, Rheumatology (Oxford), 50, 124, 10.1093/rheumatology/keq242 Bongartz, 2006, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials, JAMA, 295, 2275, 10.1001/jama.295.19.2275 Galloway, 2013, Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register, Ann Rheum Dis, 72, 229, 10.1136/annrheumdis-2011-201108 Arvin, 2005, Aging, immunity, and the varicella-zoster virus, N Engl J Med, 352, 2266, 10.1056/NEJMp058091 Thomas, 2004, What does epidemiology tell us about risk factors for herpes zoster?, Lancet Infect Dis, 4, 26, 10.1016/S1473-3099(03)00857-0 McDonald, 2009, Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis, Clin Infect Dis, 48, 1364, 10.1086/598331 Strangfeld, 2009, Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, JAMA, 301, 737, 10.1001/jama.2009.146 Greenberg, 2010, Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry, Ann Rheum Dis, 69, 380, 10.1136/ard.2008.089276 Winthrop, 2013, Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster, JAMA, 309, 887, 10.1001/jama.2013.1099 Sakai, 2012, Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis, Arthritis Care Res, 64, 1125 Perez-Zafrilla, 2008, Rates of herpes zoster in patients with rheumatoid arthritis and treatment with TNF antagonists. Incidence rate in BIOBADASER cohort in comparison with EMECAR cohort [abstract FRI0129], Ann Rheum Dis, 67, 327 Titton, 2010, Biologic register in a developing country: safety is different from european registries? The biobadabrasil first results [abstract AB0958], Ann Rheum Dis, 69, 717 Inanc, 2006, Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis, Rheumatol Int, 27, 67, 10.1007/s00296-006-0165-9 Lovell, 2008, Adalimumab with or without methotrexate in juvenile rheumatoid arthritis, N Engl J Med, 359, 810, 10.1056/NEJMoa0706290 Widdifield, 2010, The incidence of herpes zoster in seniors with rheumatoid arthritis [abstract 341], Arthritis Rheum, 62, S142 Ruperto, 2007, A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis, Arthritis Rheum, 56, 3096, 10.1002/art.22838 Torii, 2010, Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial, J Dermatol Sci, 59, 40, 10.1016/j.jdermsci.2010.04.014 Emery, 2008, Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial, Lancet, 372, 375, 10.1016/S0140-6736(08)61000-4 Giannini, 2009, Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis, Arthritis Rheum, 60, 2794, 10.1002/art.24777 Failla, 2012, Herpes zoster in patients treated with biologicals, Dermatology (Basel), 224, 251, 10.1159/000338691 Guillén Astete, 2010, Juvenile idiopathic arthritis on biologic treatment: new onset adverse events [abstract AB0803], Ann Rheum Dis, 69, 708 Konttinen, 2007, Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience, Clin Rheumatol, 26, 1693, 10.1007/s10067-007-0574-5 Levälampi, 2008, Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment, Rheumatol Int, 28, 261, 10.1007/s00296-007-0436-0 Suwannalai, 2009, The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital, Int J Rheum Dis, 12, 118, 10.1111/j.1756-185X.2009.01393.x Wendling, 2008, Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease, Joint Bone Spine, 75, 540, 10.1016/j.jbspin.2007.10.011 Horneff, 2009, Tolerance of tumour necrosis factor alpha blockade with etanercept in 1014 patients with juvenile idiopathic arthritis [abstract OP-0293], Ann Rheum Dis, 68, 169 Su, 2009, Improvement of active rheumatoid arthritis after etanercept injection: a single-center experience, J Chin Med Assoc, 72, 581, 10.1016/S1726-4901(09)70433-2 Tzaribachev, 2008, Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years, Rheumatol Int, 28, 1031, 10.1007/s00296-008-0563-2 Weinblatt, 2011, Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis, Arthritis Care Res (Hoboken), 63, 373 Saougou, 2010, Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study, Joint Bone Spine, 77, 325, 10.1016/j.jbspin.2010.02.014 Sleptsova, 2010, Efficay of treatment with infliximab in patients with early and long-standing oligo- and polyarticular juvenile idiopathic arthritis [abstract SAT0467], Ann Rheum Dis, 69, 639 Schiff, 2008, Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate, Ann Rheum Dis, 67, 1096, 10.1136/ard.2007.080002 Furst, 2010, The risk of infections with biologic therapies for rheumatoid arthritis. Semin, Arthritis Rheum, 39, 327, 10.1016/j.semarthrit.2008.10.002 Botsios, 2008, Infections during tumour necrosis factor-alpha and interleukin-1 blocking therapy for rheumatoid arthritis and spondylarthropathies in daily practice. 7 years experience with 726 patients in a single italian academic center [abstract THU0126], Ann Rheum Dis, 67, 175 Tubach, 2010, The risk of non tuberculosis opportunistic infections is higher in patients treated with infliximab or adalimumab than in patients treated with etanercept. Results of the 3-year prospective french RATIO registry [abstract SAT0113], Ann Rheum Dis, 69, 523 Koike, 2009, Postmarketing surveillance of the safety and effectiveness of etanercept in Japan, J Rheumatol, 36, 898, 10.3899/jrheum.080791 Smitten, 2007, The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom, Arthritis Rheum, 57, 1431, 10.1002/art.23112 Wolfe, 2006, Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders, Rheumatology (Oxford), 45, 1370, 10.1093/rheumatology/kel328 Suarez-Almazor, 2000, Cyclophosphamide for treating rheumatoid arthritis, Cochrane Database Syst Rev Online, 4, CD001157 García-Doval, 2010, Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists, Ann Rheum Dis, 69, 1751, 10.1136/ard.2009.125658 Lipsky, 2000, Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group, N Engl J Med, 343, 1594, 10.1056/NEJM200011303432202 Maini, 2004, Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate, Arthritis Rheum, 50, 1051, 10.1002/art.20159 Keystone, 2004, Arthritis Rheum, 50, 1400, 10.1002/art.20217 Furst, 2003, Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis), J Rheumatol, 30, 2563 Moreland, 2006, Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience, J Rheumatol, 33, 854 Wallis, 2004, Granulomatous infectious diseases associated with tumor necrosis factor antagonists, Clin Infect Dis, 38, 1261, 10.1086/383317 Salmon-Ceron, 2011, Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry, Ann Rheum Dis, 70, 616, 10.1136/ard.2010.137422 Dixon, 2010, Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR), Ann Rheum Dis, 69, 522, 10.1136/ard.2009.118935 Tubach, 2009, Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry, Arthritis Rheum, 60, 1884, 10.1002/art.24632 Serac, 2012, Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry, J Invest Dermatol, 132, 726, 10.1038/jid.2011.383 Haider, 2007, Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes, J Invest Dermatol Symp Proc, 12, 9, 10.1038/sj.jidsymp.5650032 Harpaz, 2008, Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, 57, 1 Zhang, 2012, Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases, JAMA, 308, 43, 10.1001/jama.2012.7304 Veetil, 2011, Incidence and time trends of herpes zoster in rheumatoid arthritis: a population based Cohort Study [abstract 1187], Arthritis Rheum, 63, S462